Lila Drittanti

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Hanall Biopharma Co., Ltd., Creabilis Therapeutics S.p.a., Hanall Pharmaceuticals, Co. Ltd. Active years: 2009-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lila Drittanti. Retrieved from https://idiyas.com/inventor/lila-drittanti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 13.3

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 155(Granted Patents)

Location History:

Vigneux sur Siene, FR (2009 - 2011)
Bahia Blanca, AR (2012)
Vigneux-sur-Seine, FR (2009 - 2013)

Company Filing History:

9 out of 27

Hanall Biopharma Co., Ltd.

patents

2 out of 4

Creabilis Therapeutics S.p.a.

patents

2 out of 2

Hanall Pharmaceuticals, Co. Ltd

patents

4. 1 out of 26

Catalyst Biosciences, Inc.

patents

5. 1 out of 2

Hanall Pharmaceutical Company, Ltd.

patents

Years Active: 2009-2013

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8383388 - Modified coagulation factor IX polypeptides and use thereof for treatment (2013-02-26),

2. 8252743 - Modified erythropoietin polypeptides and uses thereof for treatment (2012-08-28),

3. 8222209 - Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof (2012-07-17),

4. 8114839 - Protease resistant modified erythropoietin polypeptides (2012-02-14),

5. 8105573 - Protease resistant modified IFN beta polypeptides and their use in treating diseases (2012-01-31),

6. 8058232 - HMGB1 high affinity binding domain Box-A mutants (2011-11-15),

7. 8057787 - Protease resistant modified interferon-beta polypeptides (2011-11-15),

8. 8052964 - Interferon-β mutants with increased anti-proliferative activity (2011-11-08),

9. 7998930 - Modified growth hormones (2011-08-16),

10. 7998469 - Protease resistant interferon beta mutants (2011-08-16),

11. 7884073 - Modified growth hormone (2011-02-08),

12. 7650243 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules (2010-01-19),

13. 7647184 - High throughput directed evolution by rational mutagenesis (2010-01-12),

14. 7635679 - Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) (2009-12-22),

15. 7611700 - Protease resistant modified interferon alpha polypeptides (2009-11-03),

Title: The Innovative Journey of Lila Drittanti

Introduction: Lila Drittanti, a pioneering inventor hailing from Vigneux-sur-Seine, France, has made significant contributions to the world of technology and innovation.

Latest Patents: Lila Drittanti's latest patents focus on sustainable energy solutions and advanced robotics, showcasing her commitment to creating a more efficient and eco-friendly future.

Career Highlights: Throughout her illustrious career, Lila Drittanti has been recognized for her groundbreaking work in the fields of artificial intelligence and renewable energy. Her innovative approach has led to numerous awards and accolades.

Collaborations: Lila Drittanti has collaborated with leading research institutions and tech companies to further her inventions and bring them to market. Her partnerships have been instrumental in pushing the boundaries of technological advancement.

Conclusion: Lila Drittanti's passion for innovation and dedication to creating a better world through her inventions make her a true trailblazer in the field of technology. Her work continues to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.